Skandinaviska Enskilda Banken AB publ Buys 1,900 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Skandinaviska Enskilda Banken AB publ increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,913 shares of the company's stock after buying an additional 1,900 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in IDEXX Laboratories were worth $7,806,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Geode Capital Management LLC lifted its position in IDEXX Laboratories by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after purchasing an additional 40,349 shares during the period. Franklin Resources Inc. lifted its holdings in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after acquiring an additional 34,305 shares during the period. Amundi lifted its holdings in shares of IDEXX Laboratories by 8.1% during the 4th quarter. Amundi now owns 758,669 shares of the company's stock worth $328,018,000 after acquiring an additional 56,837 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of IDEXX Laboratories by 0.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 751,900 shares of the company's stock worth $379,875,000 after acquiring an additional 2,463 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in IDEXX Laboratories by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company's stock valued at $219,823,000 after acquiring an additional 16,213 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have weighed in on IDXX shares. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Morgan Stanley decreased their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Up 0.6 %

NASDAQ IDXX traded up $2.63 on Wednesday, reaching $422.15. The company had a trading volume of 463,314 shares, compared to its average volume of 548,742. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company's fifty day moving average is $437.74 and its 200 day moving average is $445.87. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $548.88. The stock has a market capitalization of $34.33 billion, a P/E ratio of 39.56, a P/E/G ratio of 3.41 and a beta of 1.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.